Cocrystal Pharma, Inc. (COCP)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development | 1,122 | |||
| General and administrative | 986 | |||
| Total operating expenses | 2,108 | |||
| Loss from operations | -2,108 | |||
| Interest income, net | -28 | |||
| Foreign exchange gain (loss) | 25 | |||
| Total other income, net | 53 | |||
| Net loss | -2,055 | |||
| Net loss per common share, basic | -0.2 | |||
| Net loss per common share, diluted | -0.2 | |||
| Weighted average number of common shares, basic | 10,174,000 | |||
| Weighted average number of common shares, diluted | 10,174,000 | |||